Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt Study

AIDS

Volumn 14, Issue 10, 2000, Pages 1333-1339

  Durant, J ^a   Clevenbergh, P ^a   Garraffo, R ^b   Halfon, P ^c   Icard, S ^b   Del Giudice, P ^d   Montagne, N ^f   Schapiro, J M ^e   Dellamonica, P ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b Clinical Pharmacokinetics Unit   (France)

^c Laboratoire Alphabio   (France)

^d Bonnet Hospital   (France)

^e National Hemophilia Center   (Israel)

^f Hôpital de l'Archet ^*

Author keywords

Drug monitoring; Genotype; HIV; Pharmacokinetics; Resistance

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADULT; DRUG RESISTANCE, MICROBIAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; TREATMENT FAILURE;

EID: 0033942065     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200007070-00005     Document Type: Article

References (22)

1. 1. Durant J, Clevenbergh P, Halfon P, et al. Drug resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet 1999, 353:2195-2199.
2. 2. Drusano G, Sadler B, Millard J, et al. Pharmacodynamics of 141W94 as determined by short term change in HIV RNA: influence of viral isolate baseline EC50. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, 1997 [Abstract A16].
3. 3. Acosta E, Henry K, Wekker D, et al. Indinavir pharmacokinetics and relationship between exposure and antiviral effect. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, 1997 [Abstract A15].
4. 4. Schapiro J, Winters M, Stewart F, et al. The effect of high dose saquinavir on viral load and CD4 T-cell counts in HIV-infected patients. Ann Intern Med 1996, 124:1039-1050.
5. 5. Danner S, Carr A, Leonard J, et al. A short term study of the safety, pharmacokinetics and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995, 333:1528-1533.
6. 6. Hoetelmans R, Heeswijk R, Meenhorst P, et al. Plasma concentrations of saquinavir (SQV) determine HIV-RNA response over a 48-week period. 12th World AIDS Conference. Geneva, 28 June-3 July 1998 [Abstract 511/42261].
7. 7. Burger D, Hoetelmans R, Hugen P, et al. Plasma level of indinavir and virological treatment failure in HIV infected patients. J Chromatogr B 1997; 703:235.
8. 8. Lorenzi P, Yerly S, Abderrakim K, et al. Toxicity, efficacy, plasma drug concentration and protease mutations in patients with advanced HIV infection treated with ritonavir and saquinavir. AIDS 1997, 11:F95-F99.
9. 9. Hoetelmans R, Reijers M, Weverling G, et al. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS 1998, 12:F111-F115.
10. 10. Hoetelmans R, Reijers M, Weverling G, et al. The rate of decline of HIV-1 RNA in plasma correlates with nelfinavir concentrations in plasma. 12th World AIDS Conference. Geneva, 28 June-3 July 1998 [Abstract 510/42259].
11. 11. Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: recommendations of an international panel. JAMA 1998, 280:78-86.
12. 12. Wolf E, Au T, Haddix H, Matusewsky. Determination of L-753524, an human immunodeficiency virus protease inhibitor, in human plasma and urine via high performance liquid chromatography with column switching. J Chromatogr A 1995, 692: 42-45.
13. 13. Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 1996, 51:701-712.
14. 14. Hsu A, Granneman GR, Bertz RJ. Ritonavir clinical pharmacokinetics and interactions with others anti-HIV agents. Clin Pharmacokinet 1998, 35:275-291.
15. 15. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection. Consensus Statement. JAMA 1998, 279:1984-1991.
16. 16. Jimenez-Nacher I, Soriano V. Interactions of antiretroviral drugs. AIDS Rev 1999, 1:116-123.
17. 17. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998, 101:289-294.
18. 18. Descamps D, Peytavin G, Calvez V, et al. and the Trilege study group, France. Virologic failure, resistance and plasma drug concentration in induction maintenance therapy trial (ANRS 072 Trilège). 6th Conference on Retroviruses and Opportunistic Infection. Chicago, 1999 [Abstract 493].
19. 19. Habrich RH, Little SJ, Currier JS, for the California Collaborative Treatment Group. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS 1999, 13:1099-1107.
20. 20. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confer resistance to ritonavir. Nat Med 1996, 2:760-766.
21. 21. Livingston DJ, Pazhanisamy S, Porter DJ, Parteladis JA, Tung RD, Painter GR. Weak binding of VX-78 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J Infect Dis 1995, 172:1238-1245.
22. 22. Molla A, Vasavanonda S, Kumar G, et al. Human serum attenuates the activity of protease inhibitors toward wild type and mutant human immunodeficiency virus. Virology 1998, 250:255-262.